Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  06:22 2022-08-09 am EDT
53.08 EUR   -0.08%
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 - Form 6-K
PU
08/08Galapagos receives transparency notification from FMR LLC
GL
08/08Galapagos receives transparency notification from FMR LLC
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call

06/22/2022 | 08:00am EDT
share with twitter
share with LinkedIn
share with facebook
Welcome all to the Galapagos' webcast on the acquisition of CellPoint and the Abound Bio that we announced last night. Thank you all for joining. This recorded webcast is accessible via the...


© S&P Capital IQ 2022
All news about GALAPAGOS NV
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 ..
PU
08/08Galapagos receives transparency notification from FMR LLC
GL
08/08Galapagos receives transparency notification from FMR LLC
AQ
08/08RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 557 M 569 M 569 M
Net income 2022 -143 M -146 M -146 M
Net cash 2022 3 478 M 3 555 M 3 555 M
P/E ratio 2022 -26,5x
Yield 2022 -
Capitalization 3 491 M 3 568 M 3 568 M
EV / Sales 2022 0,02x
EV / Sales 2023 0,57x
Nbr of Employees 1 305
Free-Float 73,7%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 53,12 €
Average target price 60,56 €
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV7.92%3 568
MODERNA, INC.-26.44%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-16.80%43 579
SEAGEN INC.13.72%32 890
ALNYLAM PHARMACEUTICALS, INC.28.89%27 695